DAVID C. STOLINSKY, M.D.
This content is PDF only. Please click on the PDF icon to access.
To the editor: In their excellent article on combination chemotherapy of advanced Hodgkin's disease (Ann Intern Med 73:881-895, 1970) DeVita and associates describe the use of prednisone in the first and fourth of the six courses of therapy. There seems to be a suggestion that the fourth course was better tolerated. The median WBC count was slightly higher than those of the preceding or subsequent courses, fewer patients experienced severe leukopenia, and the mean dose of the alkylator was higher than for the preceding or subsequent courses. Do the authors have the impression that prednisone improved the marrow's tolerance of
STOLINSKY DC. Chemotherapy for Hodgkin's. Ann Intern Med. ;74:640. doi: 10.7326/0003-4819-74-4-640_1
Download citation file:
Published: Ann Intern Med. 1971;74(4):640.
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use